PROBASE Publikationen

Discordant prostate specific antigen test results despite WHO assay standardization.
Boegemann M, Arsov C, Hadaschik B, Herkommer K, Imkamp F, Nofer JR, Gerß J, Albers P, Semjonow A.
Int J Biol Markers. 2018 Aug;33(3):275-282. doi: 10.1177/1724600818754750. Epub 2018 May 8.

[Prostate cancer screening: controversies and suggested solutions].
Al-Monajjed R, Arsov C, Albers P.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Dec;61(12):1544-1550. doi: 10.1007/s00103-018-2840-x. Review. German.
PMID: 30397721

[Effect of performing a single PSA screening : The CAP trial].
Al-Monajjed R, Arsov C, Albers P.
Urologe A. 2018 Sep;57(9):1137-1138. doi: 10.1007/s00120-018-0678-3. German. No abstract available.
PMID: 29796696

PSA screening – for whom and when?
Albers P.
Asian J Androl. 2017 Sep 5. doi: 10.4103/aja.aja_37_17. [Epub ahead of print] No abstract available.
PMID: 28879867

PSA-based early detection of prostate cancer
Albers P, Arsov C, Hiester A, Quentin M, Schimoller L, Antoch G, Rabenalt R.
Onkologe.2016 Aug; 22(8):558-561

Risk-adapted PSA screening and the PROBASE trial
Arsov C, Becker N, Albers P.
Onkologe. 2015 Sep; 21(9):778-786

PSA-based screening. Boon or bane?
Esch L, Arsov C, Albers P.
Onkologe. 2103 Sep; 19(9):705-710

Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.
Arsov C, Becker N, Hadaschik BA, Hohenfellner M, Herkommer K, Gschwend JE, Imkamp F, Kuczyk MA, Antoch G, Kristiansen G, Siener R, Semjonow A, Hamdy FC, Lilja H, Vickers AJ, Schröder FH, Albers P.
Eur Urol. 2013 Dec;64(6):873-5. doi: 10.1016/j.eururo.2013.05.022. Epub 2013 May 14. No abstract available.
PMID: 23707067